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This article introduces a manually curated data collection for gene expression meta-analysis of patients with ovarian cancer
and software for reproducible preparation of similar databases. This resource provides uniformly prepared microarray data
for 2970 patients from 23 studies with curated and documented clinical metadata. It allows users to efficiently identify
studies and patient subgroups of interest for analysis and to perform meta-analysis immediately without the challenges
posed by harmonizing heterogeneous microarray technologies, study designs, expression data processing methods and
clinical data formats. We confirm that the recently proposed biomarker CXCL12 is associated with patient survival, inde-
pendently of stage and optimal surgical debulking, which was possible only through meta-analysis owing to insufficient
sample sizes of the individual studies. The database is implemented as the curatedOvarianData Bioconductor package for
the R statistical computing language, providing a comprehensive and flexible resource for clinically oriented investigation
of the ovarian cancer transcriptome. The package and pipeline for producing it are available from http://bcb.dfci.harvard.
edu/ovariancancer.
Database URL: http://bcb.dfci.harvard.edu/ovariancancer
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Introduction
A wealth of genomic data, in particular microarray data, is
publicly available through diverse online resources. Major
databases of gene expression data, e.g. the Gene
Expression Omnibus (GEO) (1) and ArrayExpress (2), offer
the potential to identify sets of genes predictive of cancer
survival and of patient resistance to chemotherapy using
thousands of samples from multiple laboratories. Such
high numbers of samples are needed to robustly identify
and validate gene signatures for incorporation into routine
clinical practice (3). However, inconsistent formatting
among database interfaces, expression data storage and
clinical metadata annotations present formidable obstacles
to making efficient use of these resources.
Existing resources aiming to make large-scale high-
dimensional analysis across multiple studies tend to serve
only a few specifically targeted needs. To develop reprodu-
cible biomarker discovery methods appropriate for clinical
translation, a data resource must be accurate and retain
clinical variables of known importance as much as possible.
The insilicoDB (4) project provides many curated gene
expression data sets; however, it is not a focused resource
in terms of retention or quality assurance of clinical
.............................................................................................................................................................................................................................................................................................
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited. Page 1 of 10
(page number not for citation purposes)
Database, Vol. 2013, Article ID bat013, doi:10.1093/database/bat013
.............................................................................................................................................................................................................................................................................................annotations, or retention of all relevant data sets and clin-
ical variables for any one cancer type. The other major
database of curated gene expression studies, the Gene
Expression Atlas (2), provides machine- rather than manu-
ally annotated data, resulting in reduced consistency of an-
notation across studies. These are among the only
databases that offer basics such as uniform gene identifiers
to enable cross-study analysis, and then for only the most
common microarray technologies. Carey et al. (5) describe a
framework for the curation, annotation and storage of
microarray and high-throughput data in general. This
framework allows, for example, institutions to provide
researchers access to in-house and public data in a standar-
dized and convenient fashion. However, there is no existing
database that provides these resources for ovarian cancer.
Ovarian cancer is the fifth-leading cause of cancer
deaths among women (6) and has been the focus of
numerous clinical transcriptome investigations. The
curatedOvarianData database is the result of a focused
effort to enable meta-analysis of these studies and to pro-
vide the highest quality and most comprehensive gene ex-
pression data resource for any cancer. It provides
standardized gene expression and clinical data for 2970
ovarian cancer patients from 23 studies spanning 11 gene
expression measurement platforms, in the form of docu-
mented ExpressionSet objects for R/Bioconductor (7).
Gene expression data were collected from public databases
and author websites, processed in a consistent manner and
mapped uniformly to official Human Gene Nomenclature
Committee (HGNC) (8) gene symbols. Curation of clinical
annotations was machine-checked for correctness of syntax
and human-checked by two individuals to ensure accuracy.
This data package is geared primarily towards bioinfor-
matic and statistical researchers, providing an ideal re-
source for development and assessment of algorithms for
high-dimensional classification, clustering and survival ana-
lysis. It will also be valuable to ovarian cancer researchers
for biomarker identification and validation. In addition to
providing all publicly available gene expression studies with
patient survival in common forms of ovarian cancer, it in-
cludes tumours of rare histologies, normal tissues and un-
common early-stage tumours. Special effort is made to
retain the most important clinical variables from
author-provided metadata and from the original publica-
tions: overall survival, optimal debulking surgery and
tumour stage, grade and histology.
We also developed a software pipeline for automated
and reproducible production of this and comparable data
libraries.Thepipelineincludesacontrolledlanguageforcur-
ation of clinical annotations, defined by a template, which is
intuitive for non-programmers to create and edit, but which
is also used directly for machine syntax checking of curated
annotations. The pipeline handles all steps of the process
including data download, microarray preprocessing,
merging of duplicate probe sets and sample technical repli-
cates, up-to-date probe-set to gene mapping and building
of the R/Bioconductor objects and package.
One important application of the database is testing of
hypothesized prognostic markers of ovarian cancer using
multiple independent studies. We validated a recently pro-
posed independent prognostic indicator of ovarian cancer,
CXCL12 (9), using 13 published studies, demonstrating for
this biomarker that numerous studies are needed to over-
come the lack of power in individual studies of smaller
sample size. We provide code in the documentation of
the curatedOvarianData package demonstrating how this
comprehensive analysis, which was previously impractical to
achieve, is a straightforward application of the database.
Methods and implementation
The pipeline for creating the data package from public
databases (Table 1) is fully automated, with the exceptions
of manual curation of clinical annotations (Figure 1). This
manual curation was integrated in the pipeline with short R
scripts that reformat user-provided annotations into a stan-
dardized template, which largely follows the format of The
Cancer Genome Atlas (29). This template is provided in
Table 2 and used as a unit test in the curatedOvarianData
package, i.e. the curation is automatically checked for valid
values in the package building process. Downloading
phenotype data and expression data from GEO (1), syntax
validation of curated clinical metadata, microarray data
preprocessing, normalization, gene mapping and the cre-
ation of Bioconductor ‘ExpressionSet’ objects, which link
gene expression data and phenotype annotations, were
fully automated. The generation of the package is repro-
ducible using the pipeline provided at https://bitbucket.org/
lwaldron/curatedovariandata.
Data acquisition and curation
Our search for clinically annotated ovarian cancer micro-
array studies identified 21 published studies, which pro-
vided 23 publicly available data sets from various sources
(Table 1). The search not only targeted studies of primary
tumours annotated with patient survival but also included
studies providing other potentially valuable clinical anno-
tation. Other main factors of interest included drug resist-
ance, outcome of the primary tumour debulking surgery,
histology, stage and grade. We excluded studies not mea-
suring gene expression (i.e. studies of genomic copy
number), studies of cell lines, animal models, or
non-primary tumours, and data sets not providing clinical
information. Expression and clinical data were obtained
from the two major public repositories GEO (i) and
ArrayExpress (ii), otherwise from supplementary data of
the original publications. Data from GEO were obtained
using the GEOquery package (31). Clinical annotations
.............................................................................................................................................................................................................................................................................................
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original uncurated annotations were retained as a single
field. Curated annotations were checked by syntax against
a template, which standardized all the known clinically
relevant indicators and allowable data values. Clinical
data were twice independently curated (authors B.G. and
T.R.), and all discrepancies were resolved for the final ver-
sion. The availability of clinical data varied substantially
across datasets (Figure 2).
Gene expression processing and gene mapping
Where raw data from Affymetrix U133a or U133 Plus 2.0
platforms were available, these were pre-processed by
frozen Robust Multi-array Analysis (fRMA) (32), for other
Affymetrix platforms by Robust Multi-array Average
(RMA) (33), and otherwise we used pre-processed data as
provided by the authors. Up-to-date maps from probe set
IDs to gene symbols were obtained from BioMart (34).
Where BioMart maps were not available but target se-
quences were provided for the microarray platforms, we
used the BLAST algorithm (35) to map these sequences
against the human genome (build GRCh37) and to identify
the gene transcript targeted by each probe. Otherwise, the
annotations provided with the platform on GEO were used.
In the curatedOvarianData version of the package, genes
with multiple probe sets were represented by the probe set
with the highest mean across all data sets of the sample
platform (36), and this original probe set identifier was also
stored in the ExpressionSet object (7). We selected the same
representative probe set for all studies of a common micro-
array platform. Finally, we provide two alternative versions
of the package: NormalizerVcuratedOvarianData, where
redundant probe sets are averaged after filtering probe
sets with low correlation to their redundant probe sets,
Table 1. Data sets in the curatedOvarianData database
Data set Reference Platform Samples Late
Stage
a
(%)
Serous
Subtype (%)
Median
Survival
(Months)
Median
Follow-up
(Months)
Censoring
(%)
E.MTAB.386 (10) Ill. HumanRef-8 v2 129 99 100 42 55 43
GSE12418 (11) SWEGENE v2.1.1_27k 54 100 100 N/A N/A N/A
GSE12470 (12) Agilent G4110b 53 66 81 N/A N/A N/A
GSE13876 (13) Operon Human v3 157 100 100 25 72 28
GSE14764 (14) Affy U133a 80 89 85 54 37 74
GSE17260 (15) Agilent G4112a 110 100 100 53 47 58
GSE18520 (16) Affy U133 Plus 2.0 63 84 84 25 140 23
GSE19829.GPL570 (17) Affy U133 Plus 2.0 28 N/A N/A 47 62 39
GSE19829.GPL8300 (17) Affy U95 v2 42 N/A N/A 45 50 45
GSE20565 (18) Affy U133 Plus 2.0 140 48 51 N/A N/A N/A
GSE2109 N/A Affy U133 Plus 2.0 204 42 42 N/A N/A N/A
GSE26712 (19) Affy U133a 195 96 95 46 90 30
GSE30009 (20) TaqMan qRT-PCR 380 103 100 99 41 53 45
GSE30161 (21) Affy U133 Plus 2.0 58 100 81 50 83 38
GSE32062.GPL6480 (22) Agilent G4112a 260 100 100 59 56 53
GSE32063 (22) Agilent G4112a 40 100 100 53 81 45
GSE6008 (23) Affy U133a 99 54 41 N/A N/A N/A
GSE6822 (24) Affy Hu6800 66 N/A 62 N/A N/A N/A
GSE9891 (25) Affy U133 Plus 2.0 285 85 93 47 36 59
PMID15897565
b (26) Affy U133a 63 83 100 N/A N/A N/A
PMID17290060
c (27) Affy U133a 117 98 100 63 82 43
PMID19318476 (28) Affy U133a 42 93 100 34 89 48
TCGA (29) Affy HT U133a 578 90 98 45 52 48
These data sets provide curated gene expression and clinical data for a total of 2970 samples, including all publicly ovarian cancer gene
expression experiments with individual patient survival information at the time of press.
aOnly FIGO Stages III and IV.
bData set is a subset of the samples from the retracted paper PMID17290060, Dressman et al. (27).
cPaper was retracted because of a misalignment of genomic and survival data (30); the corrected data are provided here.
N/A, not available.
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from downloading of data to final packaging, requiring manual intervention only for identifying studies, curation of clinical
metadata and documentation of the package.
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for computational functional genomics (37), and
FULLVcuratedOvarianData, which does not collapse redun-
dant probe sets targeting the same gene transcript but in-
stead provides a probe set to gene symbol map in the
featureData slot of each ExpressionSet.
Final packaging
Technical replicate samples were merged by averaging.
Microarray expression data and clinical metadata were
then represented as ExpressionSet objects (7) for each
study. The ExpressionSet objects were also populated with
citations, platform identifiers and details, data preprocess-
ing methods and warnings of retracted papers (27) and
specimens also used in other studies (26, 28, 29, 38).
ExpressionSets were packaged as the curatedOvarianData
R library, which provides a reference manual including
descriptions of the syntax template and summaries of the
annotations, citation, microarray platform and other infor-
mation for each study.
Discussion
We introduce a data package for the R/Bioconductor stat-
istical programming environment that includes all current
major ovarian cancer gene expression data sets (Table 1).
The process of downloading clinically annotated public
genomic data and proceeding to a final computational ana-
lysis is, despite recent efforts (4, 5), still long and prone to
errors. This is particularly true when the various data sets
need to be comparable for meta-analyses, which requires a
fully standardized annotation. Our data resource provides a
comprehensive and highly curated resource for efficient
meta-analysis of the ovarian cancer transcriptome, for
Figure 2. Available clinical annotation. This heatmap visualizes for each curated clinical characteristic (rows) the availability in
each data set (columns). Red indicates that the corresponding characteristic is available for at least one sample in the data set.
See Table 2 for descriptions of these characteristics.
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ment. It additionally provides a complete computational
pipeline to reproduce this process for other cancers or
data sources.
Two common problems of publicly available genomic
data are the scarcity of clinical annotation and inconsistent
definitions of clinical characteristics across independent
data sets (5). In our review of original papers and curation
of clinical annotations, we were however able to retain, in
most studies, the clinical variables of proven importance:
overall survival, age, optimal debulking surgery, tumour
histology, grade and stage (Figure 2). Other characteristics
such as detailed treatment information or recurrence free
survival times were rarely available; however, ovarian
cancer has a relatively standard treatment regimen of plat-
inum chemotherapy and no radiotherapy. The most import-
ant clinical variables were in general consistently defined
between studies, with these definitions provided in Table 2.
Notably, all studies used the Federation of Gynecology and
Obstetrics (FIGO) staging system, and all but one study (11)
defined suboptimal debulking surgery as residual tumour
mass>1cm (Table 2). The relatively large number of
well-annotated data sets in this database may allow inter-
esting future work, addressing the problem of recovering
missing annotations from genomic data only (40).
One important use of this database is the assessment of
prognostic biomarkers. As a demonstration, we examined a
recent study by Popple et al. (9), which analysed the expres-
sion of the chemokine protein CXCL12 using a tissue micro-
array of 289 primary ovarian cancers. CXCL12/CXCR4 is a
chemokine/chemokine receptor axis that has previously
been shown to be directly involved in cancer pathogenesis
(41, 42). Ovarian cancer constitutively expresses CXCL12 and
CXCR4, and both tumour CXCL12/CXCR4 expression and
stroma-derived CXCL12 expression have been reported to
be prognostic factors in human ovarian cancer (41). Popple
et al. found that high levels of CXCL12 protein were asso-
ciated with significantly poorer survival compared with pa-
tients whose tumours produce low amounts of this
chemokine, independently of stage, residual disease (opti-
mal debulking) and adjuvant chemotherapy. The patient
cohort was heterogeneous, with various histologic types,
grades and stages, leaving open the question of whether
this biomarker would be generalizable to other patient
populations. Furthermore, differences in protein abun-
dance may not be associated with RNA abundance.
To investigate these questions, we analysed CXCL12 ex-
pression in all primary tumour samples included in
curatedOvarianData for which overall survival information
was available. To ensure that the expression values were on
the same scale across studies, all data sets were centred by
their means and scaled by their standard deviations. A
population hazard ratio (HR) was then pooled with a
fixed-effects model, in which the HR for each cohort was
weighted with the inverse of the standard error. This is
visualized as a forest plot in Figure 3. Although the effect
is only significant (P<0.05) in three cohorts individually,
the pooled HR is significantly larger than 1 (HR=1.15,
95% CI 1.09–1.23). HR refers to the HR between patients
differing by one standard deviation in CXCL12 expression.
This confirms the hypothesis that upregulation of CXCL12 is
associated with poor outcome in 2108 patients from 13 in-
dependent studies with mixed stage, grade and histologies.
The effect is thus small but consistently detected, empha-
sizing the importance of biomarker validation in suffi-
ciently large data collections. To assess the independence
of CXCL12 with stage and residual disease, we also analysed
the 1776 patients from 10 studies where both FIGO tumour
stage and success of debulking surgery were known.
Adjustment for these two established predictors in multi-
variate analysis had little effect on the observed association
between CXCL12 and overall survival (HR=1.13, 95% CI
1.05–1.21). These HRs are comparable in magnitude to
that reported by Popple et al. for ‘moderate’ CXCL12 stain-
ing (HR=1.215, 95% CI 0.892–1.655), but lower than re-
ported for ‘high’ staining (HR=1.684, 95% CI 1.180–
2.404). This potentially reflects that the function of this
gene is at the protein level. Consistent with previous re-
ports (9, 38), we found no significant association of the
receptor CXCR4 with overall survival (HR=0.95, 95% CI
0.9–1.01, P=0.09). These analyses are straightforward and
fully reproduced as examples in the package documenta-
tion. Additional analyses limited to more homogeneous pa-
tient subsets, e.g. limited to tumours of the same histology,
are needed, but they are another straightforward applica-
tion of the package.
In constructing curatedOvarianData, we took several
steps to minimize across-study batch effects. Where raw
Affymetrix microarray data were available, we used a stan-
dardized pre-processing protocol. All data sets from the
same platform were normalized with the same algorithms
and parameters. For the Affymetrix U133A and U133 Plus
2.0, we chose the fRMA (32) normalizing algorithm, a vari-
ant of the standard RMA (33) algorithm that uses publicly
available microarray databases to estimate probe-specific
effects and variances, instead of using only the samples
from the data set to be normalized. We provide example
code in the database documentation for removing
between-platform batch effects with the ComBat method
(43). Such a batch effect removal is typically necessary when
data sets are merged.
If different platforms are compared, then the mapping
of probe sets to common identifiers such as gene symbols is
a critical and error prone step. In particular when older
platforms are considered, care must be taken to ensure
that the probe sets target identical transcripts; gene iden-
tification is a persistent problem in genome-scale data in-
tegration. We used the BioMart database (34) to map
.............................................................................................................................................................................................................................................................................................
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current standard gene symbols. For cases in which no stable
identifiers were available, we used the BLAST algorithm
(35) to identify gene symbols from the probe oligo-
nucleotide sequences. When many genes are targeted by
more than one probe set, several approaches of collapsing
probe sets to single genes have been proposed (36, 44, 45).
In the main version of the package, we selected the probe
set with highest mean across all data sets from the same
platform to represent each gene transcript, a method
shown to perform well (36) and with the advantage of
being traceable back to a single oligonucleotide probe se-
quence for each platform. We also provide two alternative
packages with averaged and un-collapsed probe sets. The
version with un-collapsed probe sets provides current HGNC
symbols in the featureData slot of the ExpressionSet ob-
jects, which makes the application of alternative methods
for collapsing probe sets to unique gene symbols straight-
forward, e.g. with the WGCNA R package (46).
We demonstrated meta-analytical use of the package by
showing a survival association of the recently proposed
prognostic biomarker CXCL12 (9). Other possible uses in-
clude the validation of multi-gene signatures, and identifi-
cation of novel gene signatures and biomarkers for patient
survival and response to chemotherapy. Finally, this
package enables rigorous assessment of high-dimensional
machine-learning algorithms in terms of their performance
and computational requirements. We plan to continually
include newly published ovarian cancer data sets in future
versions of this package.
Conclusions
The curatedOvarianData package provides a comprehen-
sive resource of curated gene expression and clinical data
for the development and validation of ovarian cancer prog-
nostic models, the investigation of ovarian cancer subtypes
(10, 25, 29), and the comparative assessment of machine
learning algorithms for gene expression data. This database
greatly reduces the burden of time, expertise and error
involved in assembling a compendium of curated gene
expression data from tumours of known histopathology
and from patients with known clinical progression. These
advantages will be appealing to biostatisticians and bioin-
formaticians for development of analytical methods from
high-dimensional genomic data, but the database will add-
itionally provide a common, version-controlled and trans-
parent platform for reproducible investigation of the
ovarian cancer transcriptome. The pipeline for creating
this database is published under an open license and will
Figure 3. The database confirms CXCL12 as prognostic of overall survival in patients with ovarian cancer. Forest plot of the
expression of the chemokine CXCL12 as a univariate predictor of overall survival, using all 14 data sets with applicable expression
and survival information. HR indicates the factor by which overall risk of death increases with a one standard deviation increase
in CXCL12 expression. A summary HR significantly larger than 1 indicates that patients with high CXCL12 levels had poor
outcome and confirms in several lines of code the previously reported association between CXCL12 abundance and patient
survival (9). Consideration of important clinicopathological features such as stage, grade, histology and residual disease (optimal
surgical debulking) is also straightforward; examples are provided in the package vignette.
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such, we hope this database and pipeline will provide one
part of the solution to reproducibility in high-dimensional
genomic research.
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